PE20020959A1 - Derivados quimicos y su aplicacion como agentes antitelomerasa - Google Patents

Derivados quimicos y su aplicacion como agentes antitelomerasa

Info

Publication number
PE20020959A1
PE20020959A1 PE2002000227A PE2002000227A PE20020959A1 PE 20020959 A1 PE20020959 A1 PE 20020959A1 PE 2002000227 A PE2002000227 A PE 2002000227A PE 2002000227 A PE2002000227 A PE 2002000227A PE 20020959 A1 PE20020959 A1 PE 20020959A1
Authority
PE
Peru
Prior art keywords
amino
nil
methyl
triazine
quinoli
Prior art date
Application number
PE2002000227A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Mailliet
Abdelazize Laoui
Gilles Doerflinger
Francois Hamy
Thomas Caulfield
Jean-Louis Mergny
Jean-Francois Riou
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0103916A external-priority patent/FR2822468B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PE20020959A1 publication Critical patent/PE20020959A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2002000227A 2001-03-23 2002-03-22 Derivados quimicos y su aplicacion como agentes antitelomerasa PE20020959A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0103916A FR2822468B1 (fr) 2001-03-23 2001-03-23 Derives chimiques et leur application comme agent anti-telomerase
FR0110370 2001-08-02

Publications (1)

Publication Number Publication Date
PE20020959A1 true PE20020959A1 (es) 2002-12-17

Family

ID=26212933

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000227A PE20020959A1 (es) 2001-03-23 2002-03-22 Derivados quimicos y su aplicacion como agentes antitelomerasa

Country Status (11)

Country Link
EP (1) EP1373252A1 (enExample)
JP (1) JP2004524349A (enExample)
AR (1) AR034297A1 (enExample)
AU (1) AU2002251140B2 (enExample)
CA (1) CA2442012A1 (enExample)
CO (1) CO5380035A1 (enExample)
IL (2) IL158056A0 (enExample)
MX (1) MXPA03008269A (enExample)
MY (1) MY130957A (enExample)
PE (1) PE20020959A1 (enExample)
WO (1) WO2002076975A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002314252A1 (en) 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004001018A2 (en) * 2002-06-25 2003-12-31 The Center For Blood Research, Inc. Vacuolins
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2008540585A (ja) * 2005-05-19 2008-11-20 プロメティック・バイオサイエンスィズ・インコーポレーテッド 転移性メラノーマ及び他の癌を治療するための化合物、そのような化合物を含有する組成物、および治療方法
JP2009545592A (ja) * 2006-07-31 2009-12-24 プリーシス・ファーマシューティカルズ・インコーポレイテッド コード化小分子ライブラリーからのオーロラキナーゼ阻害剤
US8415340B2 (en) * 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
FR2948686B1 (fr) * 2009-07-30 2011-08-19 Biomerieux Sa Nouveaux substrats de peptidase
US20210024455A1 (en) * 2018-03-20 2021-01-28 Hiroshima University Compound which inhibits telomere-binding protein, and telomere-binding protein inhibitor containing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
IL149402A0 (en) * 1999-11-29 2002-11-10 Aventis Pharma Sa Arylamine derivatives and their use as anti-telomerase agent
ATE511858T1 (de) * 2002-02-05 2011-06-15 Astellas Pharma Inc 2,4,6-triamino-1,3,5-triazin-derivat

Also Published As

Publication number Publication date
IL158056A0 (en) 2004-03-28
EP1373252A1 (fr) 2004-01-02
CA2442012A1 (fr) 2002-10-03
MY130957A (en) 2007-07-31
IL158056A (en) 2010-02-17
JP2004524349A (ja) 2004-08-12
CO5380035A1 (es) 2004-03-31
AU2002251140B2 (en) 2007-03-15
MXPA03008269A (es) 2004-10-15
WO2002076975A1 (fr) 2002-10-03
AR034297A1 (es) 2004-02-18

Similar Documents

Publication Publication Date Title
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20010912A1 (es) Derivados arilamina y su aplicacion como agentes antitelomerasa
DE602004023838D1 (de) Hemmer der akt aktivität
DE602004026047D1 (de) Hemmer der akt aktivität
BRPI0514371A (pt) 2, 4 di (aminofenil) pirimidina como inibidores de plk
GEP20053660B (en) Novel Tyrosine Kinase Inhibitors
DE60227492D1 (de) Hemmstoffe der akt aktivität
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
PA8537501A1 (es) Naftostirilos
CO5700778A2 (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
NO20035583D0 (no) Imidazo` 1,2-A pyridinderivater for profylakse og behandling av herpes virale infeksjoner
PA8501801A1 (es) Inhibidores triciclicos de polimerasas (adp - polirribosas)
ES2172945T3 (es) Imidazotriazinonas sustituidas en 2 con fenilo como inhibidores de fosfodiesterasas.
GT200100016A (es) Pirido[2,3,-d]pirimidin-2,7-diaminas inhibidoras de cinasas.
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
YU81100A (sh) Derivati 2-(purin-9-il)tetrahidrofuran-3,4 diola
EP1633740A4 (en) CHEMICAL COMPOUNDS
SE9702564D0 (sv) New compounds
DK1483251T3 (da) C3-cyano-epothilon-derivater
AR029005A1 (es) FORMULACION LíQUIDA ESTABLE SIN AGUA O CASI SIN AGUA DE BENCIMIDAZOLES SUSTITUIDOS, PROCESO PARA SU PREPARACIoN, USO DE ESTA FORMULACIoN, Y USO DE POLIETILENGLICOL Y UNA SAL DE SODIO O POTASIO DE UN INHIBIDOR DE H+, K+-ATP ASA
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
GT200100251A (es) Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida
PE20011349A1 (es) 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
ES2079068T3 (es) 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed